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Periostin is frequently overexpressed and enhances invasion and
angiogenesis in oral cancer
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Oral squamous-cell carcinoma (OSCC) is one of the most common types of human cancer. Typically OSCC cells show persistent
invasion that frequently leads to local recurrence and distant lymphatic metastasis. We previously identified Periostin as the gene
demonstrating the highest fold change expression in the invasive clone by comparing the transcriptional profile of parent OSCC cell
line and a highly invasive clone. Here, we demonstrated that Periostin overexpression enhanced invasiveness in oral cancer cell lines.
To know the role of Periostin in invasion, angiogenesis and metastasis in OSCC cases, we first examined the expression of Periostin
mRNA in 31 OSCC cases by RT–PCR and Periostin protein in 74 OSCC cases by immunohistochemistry. Then, we compared the
Periostin expression with invasion pattern, metastasis and blood vessel density. Periostin mRNA and protein overexpression were
frequently found in OSCC cases and Periostin expression was well correlated with the invasion pattern and metastasis. Moreover,
blood vessel density of Periostin-positive cases was higher than those of Periostin-negative cases. Interestingly, recombinant Periostin
enhanced capillary formation in vitro in a concentration-dependant manner. In summary, these findings suggest that Periostin may
promote invasion and angiogenesis in OSCC, and that Periostin can be a strong marker for prediction of metastasis in oral cancer
patients.
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Cancers of the oral cavity accounts for 274 000 cases in 2002, with
almost two-thirds of them in men (Parkin et al, 2005). Squamous-
cell carcinoma of the head and neck is a heterogeneous disease
with distinct patterns of presentation and behaviour (Forastiere
et al, 2001). Individual tumour behaviour varies greatly, with some
tumours growing slowly and others rapidly or metastasising early.
Despite aggressive and multidisciplinary treatment approaches,
including preoperative or postoperative chemotherapy and/or
radiotherapy with reconstructive surgery, there has been no
significant improvement in 5-year survival over the past 20 years
(Friedlander, 2003). Review of literature indicated that the most
important factor for high mortality rate is the advanced stage of
the disease at the time of diagnosis and treatment. The molecular
genetic background facilitating this behaviour is an area of great
interest, especially in regard to invasion. Like most epithelial
cancers, oral squamous-cell carcinoma (OSCC) develops through
the accumulation of multiple genetic and epigenetic alterations in a
multistep process. The most important prognostic indicator of the
patients with OSCC is metastasis to cervical lymph nodes or
distant organs (Regezi and Sciubba, 1989). The process of
metastasis consists of sequential and selective steps, including
proliferation, induction of angiogenesis, detachment, motility,
invasion into circulation, aggregation and survival in the circula-
tion, cell arrest in distant capillary beds and extravasation into
organ parenchyma (Fidler, 1991). Recent molecular studies have
advanced our understanding of the disease and provided a
rationale to develop novel strategies for early detection, classifica-
tion, prevention and treatment. Attempts to identify the genes
involved in the metastasis are pivotal for the early prediction of
OSCC behaviour. However, the identity and time of onset of the
alterations that endow cancer cells with these metastatic functions
are largely unknown.
We previously established OSCC cell line from a metastatic
lymph node (Kudo et al, 2003). Moreover, we isolated highly
invasive clone from this cell line by using in vitro invasion assay
method (Kudo et al, 2004). Then, we compared the transcriptional
profile of parent OSCC cells and a highly invasive clone by
microarray analysis in order to identify the genes that differ in
their expression. We identified Periostin (osteoblast-specific factor
2 (fasciclin I-like)) as the gene demonstrating the highest fold
change expression in the invasive clone. Periostin is a secreted
protein, which has been suggested to function as a cell adhesion
molecule for preosteoblast and to participate in osteoblast
recruitment, attachment and spreading (Takeshita et al, 1993;
Horiuchi et al, 1999). As we expected, Periostin overexpression
enhanced invasion and anchorage-independent growth in OSCC
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cells (Kudo et al, 2006). Interestingly, Periostin-overexpressing
cells spontaneously metastasised to cervical lymph nodes and to
the lung through their aggressive invasiveness in an orthotopic
mouse model of OSCC (Kudo et al, 2006). Bao et al (2004) also
demonstrated that a colon cancer cell line with low metastatic
potential engineered to overexpress Periostin displayed a striking
phenotype of greatly accelerated tumour metastatic growth as
xenografts in the animal model system of metastasis. Previous
studies have shown that Periostin promotes metastasis and
enhances angiogenesis in breast and colon cancers (Bao et al,
2004, Shao et al, 2004). These findings indicate that (i) Periostin
overexpression may be frequently observed in various types of
cancer, and (ii) Periostin may play an important role in invasion,
angiogenesis and metastasis, as demonstrated by using cell lines
and mice model. However, it is still unclear whether Periostin
promotes invasion, angiogenesis and metastasis in actual cancer
cases. In the present study, therefore, we examined the expression
of Periostin and correlated it with invasion pattern, metastasis and
angiogenesis in OSCC cases.
MATERIALS AND METHODS
Cell culture
OSCC cell lines, HSC4 and Ca9-22 were provided by Japanese
Collection of Research Bioresources Cell Bank. They were
maintained in RPMI-1640 (Nissui Pharmaceutical Co., Tokyo,
Japan) supplemented with 10% heat-inactivated FBS (Invitrogen,
San Diego, CA, USA) and 100Uml1 penicillin–streptomycin
(Invitrogen) under conditions of 5% CO2 in air at 371C. MSCC-1
cell line was previously established in our laboratory (Kudo
et al, 2003). This cell line was maintained in keratinocyte-SFM
(Invitrogen) under a condition of 5% CO2 in air at 371C.
Retroviral-mediated gene transfer
Packaging GP-293 cells (Clontech, Palo Alto, CA, USA) were
transfected with retroviral plasmid encoding a hexa-histidine-
tagged Periostin cDNA according to the manufacturer’s instruc-
tions. A hexa-histidine-tagged Periostin cDNA was kindly
provided by Dr X-F Wang (Duke University, Durham, NC, USA).
After 48 h of transfection, the virus-containing medium was
collected and supplemented with 8 mgml1 polybrene (Sigma, St
Louis, MO, USA). Then, the culture medium of the target cells was
replaced with this viral supernatant for 24 h. This infection process
was repeated for a second time after a 12 h recovery in normal
medium. The stable clones were obtained by puromycin selection
(1mgml1) in the culture medium.
In vitro invasion assay
In vitro invasion assay was performed as described previously
(Kudo et al, 2006). Briefly, invasion was measured by use of a
24-well cell culture insert with 8 mm pores (3097, Falcon, Becton
Dickinson, Franklin Lakes, NJ, USA). The filter was coated with
20 mg of EHS extract (Iwaki Garasu, Tokyo, Japan), which was the
reconstituted basement membrane substance. The lower compart-
ment contained 0.5ml of serum-free medium. After trypsinisation,
1.5 105 cells were resuspended in 100ml of serum-free medium
and placed in the upper compartment of the cell culture insert for
18 h. After incubation, we collected the penetrating cells onto the
lower side of the filter to isolate highly invasive clones by the
method of Kalebic et al (1998) with minor modifications. To
examine the invasiveness, cells were fixed with formalin and
stained with haematoxylin. The invasiveness of the cells was
determined by counting of the penetrating cells onto the lower
side of the filter through the pores under a microscope at  100
magnification. We assayed three times and randomly selected
three fields were counted for each assay.
Patients and tissue specimens
OSCC specimens were obtained from 31 patients who underwent
surgery at Dental Hospital (Peradeniya, Sri Lanka). These tissue
specimens were immediately frozen and stored in 801C.
Informed consent was obtained from all patients for this study.
Seventy-four paraffin-embedded tumour tissues were collected
from the archives of the same hospital for immunohistochemical
staining. Clinical details and lymph node metastasis was gathered
from surgical records of the patients.
Reverse–transcription polymerase chain reaction
(RT–PCR)
Total RNA was isolated from tumour tissues using the RNeasy
Mini Kit (Qiagen, Hilden, Germany). Preparations were quantified
and their purity was determined by standard spectrophotometric
methods. cDNA was synthesised from 1 mg total RNA according to
the ReverTra Dash (Toyobo Biochemicals, Tokyo, Japan). Two
pairs of primer sequences were as follows: human Periostin,
50-GATGGAGTGCCTGTGGAAAT-30 (forward) and 50-AACTT
CCTCACGGGTGTGTC-30 (reverse) (product size, 239 bp); human
GAPDH, 50-TCCACCACCCTGTTGCTGTA-30 (forward) and 50-
ACCACAGTCCATGCCATCAC-30 (reverse) (product size, 450 bp);
human keratin 5, 50-ACAGAAGCCGAGTCCTGGTA-30 (forward)
and 50-AGATTGGCGCACTGTTTCTT-30 (reverse). Aliquots of total
cDNA were amplified with 1.25U of rTaq-DNA polymerase
(Qiagen), and amplifications were performed in a PC701 thermal
cycler (Astec, Fukuoka, Japan) for 30 cycles after an initial 30 s
denaturation at 941C, annealed for 30 s at 601C and extended for
1min at 721C in all primers. The amplification reaction products
were resolved on 1.5% agarose/TAE gels (Nacalai tesque Inc.,
Kyoto, Japan), electrophoresed at 100mV and visualised by
ethidium-bromide staining.
Histopathological and immunohistochemical analyses
The tumour tissues were fixed in 10% formalin, embedded in
paraffin and cut into 4 mm thick sections. The sections were stained
with haematoxylin and eosin for histological examination. All 74
tumours were graded according to the classification described
by Jacobsson et al (1973) as patterns I, II, III and IV. For
immunohistochemical examination of Periostin, a modification of
the streptavidin–biotin–peroxidase-complex (SABC) method was
used. The tissue sections were deparaffinised and rehydrated in a
graded series of alcohols. Endogenous peroxidase activity was
blocked with 0.3% H2O2 for 30min. The sections were microwaved
three times for 5min each in citrate phosphate buffer (pH 6.0) for
antigen retrieval. The sections were then incubated with 10%
normal bovine serum albumin in phosphate-buffered saline (PBS)
for 10min to block nonspecific background staining. A polyclonal
anti-Periostin antibody was generated by immunising the rabbits
with specific peptides (EGEPEFRLIKEGETC) for Periostin and
purified through an affinity column. Polyclonal antibody against
Periostin was applied as a primary antibody at a dilution of 1 : 100
and incubated at 41C overnight. After washing with PBS,
biotinylated goat anti-rabbit IgG was applied to the section, which
were then incubated for 1 h at room temperature. Primary
antibody was visualised with diaminobenzidine. Sections were
counterstained with haematoxylin, dehydrated and mounted.
Periostin expression was graded as positive (over 10% of tumour
cells showed strong or diffuse immunopositivity) and negative
(less than 10% of the tumour cells showed weak or focal
immunopositivity or no staining) by consideration of percentage
of positive cells and the overall intensity of immunoreactivity.
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A cutoff of 10% Periostin-positive cells was applied to separate
positive and negative expressors. Maximally selected Fisher’s exact
test was used to demonstrate that 10% was a good cutoff point
(data not shown). Three pathologists (SS, YK and IO) made all the
assessments.
Assay for blood vessel density
CD34 is an antigen present in haematopoietic progenitor cells and
endothelial cells. Anti-CD34 antibody is a highly sensitive marker
for endothelial cell differentiation and has also been studied as a
marker for vascular tumours. To investigate the relation between
angiogenesis and Periostin, we have stained all OSCC cases with
CD34 endothelial marker (Novocastra Laboratories Ltd, Newcastle,
UK) by SABC method. In order to assess blood vessel density,
we performed histomorphometric analysis. Three representative
photomicrographs (areas where Periostin is positive including
invasive front) were taken from each case stained for CD34. First,
we went through all the sections stained for Periostin and CD34
antibodies. The area that was selected had the following criteria: (i)
expression of Periostin, (ii) included invasive front and (iii) high
number of blood vessels. In some tumours, it was difficult to take
all above three criteria in one field, as Periostin-positive cells were
little far from the invasive front. Photographs of those tumours
were taken close proximal to Periostin-expressing area, including
invasive front. For Periostin-negative cases, three areas from
invasive front were selected. Any brown staining endothelial cell or
endothelial cell cluster, with or without a lumen, was considered as
a single, countable blood vessel. Stromal area was quantitatively
analysed using the digital image (Adobe Photoshop, Adobe and
Scion Image software, Scion). From each figure, total counts of blood
vessels per stromal area were taken and the average was calculated.
The results were then compared with Periostin expression.
Generation of recombinant Periostin
Full-length human Periostin cDNA was subcloned into pIZ/V5-His
vector (Invitrogen). pIZ/V5-His vector containing Periostin was
transfected into High-Five insect cells by using Cellfectin reagent
(Invitrogen). Stable clones were obtained by Zeocin selection in
the culture medium. A Ni-nitrilotriacetic acid column was used to
purify recombinant Periostin according to the manufacturer’s
instructions (Invitrogen).
In vitro angiogenesis by human umbilical vein endothelial
cells
Because the Periostin-positive tumours showed higher number of
vessels, we examined in vitro angiogenesis by using recombinant
Periostin. An angiogenesis assay kit obtained from Kurabo (Osaka,
Japan) was used according to the manufacturer’s instructions with
minor modification (Bishop et al, 1999). Human umbilical vein
endothelial cells were treated with different concentrations of
recombinant Periostin protein (0, 50, 100 and 250 ngml1) and
changed media every 3 days. We examined 3 wells data point in a
single experiment. After 12 days, the cells were fixed at room
temperature with cold 70% ethanol for 30min. The cells were
incubated with the anti-human CD31 antibody for 1 h at 371C, and
further with an alkaline phosphatase-conjugated goat anti-mouse
IgG antibody. Visualisation was achieved with 5-bromo-4-chloro-
3-indolyl phosphate-nitroblue tetrazolium. Tubule score was
estimated with the Chalkley count method under a bright-field
microscope (Fox et al, 1995).
Statistical analysis
Possible correlation between variables of the analysed tumour
samples was tested for association by the Fisher’s exact test. For
the correlation between Periostin expression and blood vessel
density, statistical significance was measured by the Welch test.
For in vitro angiogenesis assay, statistical significance of tubule
score was also measured by the Welch test. A P-value o0.05 was
required for significance.
RESULTS
High expression of periostin is well correlated with
invasion pattern and metastasis in OSCC
We previously identified Periostin as an invasion-promoting factor
of OSCC by comparing the transcriptional profile between parent
OSCC cells and a highly invasive clone (Kudo et al, 2006). To
confirm whether Periostin can enhance the invasive activity of oral
cancer cells, we examined the invasiveness by in vitro invasion
assay in Periostin transfectant OSCC cell lines (Figure 1A and B).
Periostin overexpression strongly enhanced the invasive activity in
HSC4 and Ca9-22 cells (Figure 1B). Next, in order to identify the
role of periostin in invasion and metastasis in OSCC, we examined
Periostin mRNA by RT–PCR. As shown in Figure 1C, 68% (21 of
31) of OSCC cases expressed higher levels of Periostin mRNA.
Moreover, we examined 74 OSCC tissue sections by immunohisto-
chemical staining with an antibody against human Periostin. We
checked the specificity of polyclonal Periostin antibody. Polyclonal
Periostin antibody recognised recombinant Periostin protein, His-
Periostin-transfected cells and secreted Periostin in a conditioned
media of Periostin-overexpressing cells by Western blot analysis
(Figure 1D). Then, by using this antibody, we confirmed the
immunohistochemical expression of Periostin in human period-
ontal ligament in similar to previous reports (Figure 1E). Periostin
expression was not observed in normal oral mucosae, whereas
OSCC cells expressed Periostin at higher levels (Figure 1F). Similar
to RT–PCR analysis, high expression of Periostin was frequently
observed in OSCC cases (69%, 51 out of 74 cases) (Figure 1F).
Then, we compared Periostin expression with invasion pattern and
metastasis in 74 OSCC cases. Jacobsson’s classification (patterns
I–IV) was used for evaluation of invasion patterns, as shown in
Figure 2A(Jacobsson et al, 1973). In 74 OSCC cases, there were 6,
8, 37 and 23 cases of patterns I, II, III and IV, respectively. As
described in the literature, pattern IV has higher metastatic rate
(Unal et al, 1999; Sawair et al, 2003). Interestingly, patterns I and II
were completely negative for Periostin, in contrast with pattern IV,
where all cases expressed Periostin (Figure 2B). The correlation
between Periostin expression and invasion pattern was statistically
significant (Po0.005) (Table 1). Interestingly, Periostin expression
was significantly correlated with metastasis (Po0.005) (Table 1).
Most of primary tumours, which showed metastasis were positive
for Periostin (Figure 2C).
Correlation between Periostin expression and angiogenesis
Thus, we found a possible correlation between Periostin expres-
sion and invasion pattern and metastasis. The expression of
Periostin in various types of cancers suggests that Periostin may be
intimately associated with the progression of tumour development.
In addition, we previously demonstrated that Periostin-over-
expressing OSCC cells spontaneously metastasised to cervical
lymph nodes and lung by orthotopic implantation into the tongue
(Kudo et al, 2006). As angiogenesis is an important process of
metastasis, we examined the correlation between Periostin
expression and blood vessel density. We performed an immuno-
histochemical analysis on tumour sections by utilising an antibody
against vascular endothelial cell marker CD34, an assay commonly
used to detect the presence of vascular endothelial cells. We
performed histomorphometric analysis in order to assess the blood
vessel density. Then, we compared blood vessel density with
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Figure 1 Expression of Periostin in OSCC. (A) Overexpression of Periostin in OSCC cells. Using retroviral plasmid encoding a hexa-histidine-tagged
Periostin cDNA, infection was performed in HSC4 and Ca9–22 cells, which did not express Periostin. Ectopic expression of Periostin was examined by
immunobloting with anti-His antibody. The whole lysates from all samples were blotted with Cul1 for loading control. (B) Invasion of Periostin-
overexpressing OSCC cells. The invasiveness of the cells was determined by in vitro invasion assay as described in ‘Materials and Methods’. Graph shows
number of invaded cells after 18 h in control and Periostin-overexpressing OSCC cells, HSC4 and Ca9–22. Figures show the stained (haematoxylin) lower
side of the filter where the cells penetrated. Higher number of cells was observed in Periostin-expressed cells. (C) Expression of Periostin mRNA in OSCC.
Periostin expression was examined by RT–PCR. Some tumours expressed very higher levels of Periostin. Keratin 5 was used as a loading control for the per
cent content of epithelial cells. (D) Rabbit polyclonal Periostin antibody recognises recombinant, exogenous and secreted Periostin. Expression of Periostin
was examined by Western blot analysis in recombinant Periostin itself, His-Periostin-overexpressing HSC4 cells and condition media of HSC4 and MSCC-1
cells. (E) Immunohistochemical expression of Periostin in periodontal ligament (PDL) as a positive control ( 200). D, dentin; AB, alveolar bone. (F)
Immunohistochemical expression of Periostin in OSCC. Representative cases of Periostin expression in normal epithelium (normal) and OSCC are shown.
Normal epithelium is completely negative for Periostin compared to OSCC, where most of the tumour cells expressed Periostin ( 40). (G) The graph
shows immunohistochemical expression of Periostin in 74 OSCC cases. The number of OSCC was plotted against the expression of Periostin. Sixty-nine per
cent of them are positive for Periostin.
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Periostin expression (Figure 3A). Interestingly, the tumours with
Periostin expression significantly showed higher number of vessels
(high blood vessel density) than those without Periostin expression
(Po0.005) (Figure 3B). The average of blood vessel density was
0.6670.2 and 1.0870.3 in Periostin-negative and -positive cases,
respectively (Table 1).
To address the above immunohistochemical results, we
examined whether Periostin promotes capillary formation by in
vitro angiogenesis assay. The number and the length of tubules
were higher with high concentration of recombinant Periostin
protein (Figure 3C). Tubule score was 53.375.6, 85.7711.1,
103.3712.4 and 103.377.1 after 0, 50, 100 and 250 ngml1 of
Periostin treatment, respectively (Figure 3D). Overall, Periostin
promotes capillary formation in a concentration dependant
manner.
DISCUSSION
Periostin contains an N-terminal secretory signal peptide, followed
by a cysteine-rich domain, four internal homologous repeats and
a C-terminal hydrophilic domain. Periostin is originally identified
from osteoblasts and functions as a cell adhesion molecule for
preosteoblast and to participate in osteoblast recruitment, attach-
ment and spreading (Takeshita et al, 1993; Horiuchi et al, 1999).
Previous studies showed that the expression of Periostin is
upregulated in various types of cancer, including head and neck
(Gonzalez et al, 2003), colon (Bao et al, 2004, Tai et al, 2005),
breast (Shao et al, 2004), lung (Sasaki et al, 2001c) and ovarian
cancer (Gillan et al, 2002). Here, we also found that 68% of OSCC
cases expressed Periostin mRNA and 69% of OSCC cases expressed
Periostin protein. Cumulative findings suggest that high expres-
sion of Periostin may be a common event of tumour development
in cancer. However, most of previous studies did not clarify the
relationship between Periostin expression and clinicopathological
findings.
We identified Periostin as an invasion promoting factor by
microarray analysis and demonstrated that Periostin promoted
invasion and metastasis in OSCC by in vitro and in vivo studies
using cell lines and mice (Kudo et al, 2006). Here, we confirmed
that exogenous Periostin expression strongly enhanced invasive
activity in oral cancer cells (Figure 1A and B). On the other hand,
Bao et al (2004) identified Periostin as a metastasis-related gene by
differential display analyses using mRNA samples isolated from
normal colon tissue, primary colon cancer and metastatic tumour
in the liver derived from the same patient. They found that
Periostin promoted metastasis in colon cancer by both preventing
stress-induced apoptosis in the cancer cells and augmenting
endothelial cell survival to promote angiogenesis (Bao et al, 2004).
Same group also found that Periostin enhanced VEGF receptor
Flk-1/KDR expression in endothelial cells through integrin
avb3-FAK-mediated signalling pathway (Shao et al, 2004). Taken
together, we thought that Periostin might be involved in invasion,
angiogenesis and metastasis in OSCC. However, it is still unclear
whether Periostin is involved in invasion and metastasis in actual
cancer cases. In the present study, we demonstrated the possible
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Figure 2 Correlation between Periostin expression and invasion pattern in OSCC. (A) Diagrammatic illustration of pattern of invasion, which was first
described by Jacobsson et al (1973). Pattern I shows a solid sheet of tumour with a pushing border and the pattern II shows large tumour islands. Pattern III
shows thin strands of tumour and small tumour islands and pattern IV shows individual tumour cells. (B) Bar chart showing the relationship between
expression of Periostin and pattern of invasion. Patterns I and II are completely negative for Periostin in contrast with pattern IV where all tumours showed
positive results. (C) Relationship between Periostin expression and metastasis. Most of lymph node metastatic tumours expressed Periostin.
Table 1 Correlation between Periostin expression and clinico-patholo-
gical findings in OSCC
Periostin expression
Number of
cases Negative Positive P-value
OSCC 74 23 (31%) 51 (69%)
Invasion pattern
Po0.005
I 6 6 (100%) 0 (0%)
II 8 8 (100%) 0 (0%)
III 37 9 (24.3%) 28 (75.7%)
IV 23 0 (0%) 23 (100%)
Blood vessel density
(average)
0.6670.2 1.0870.3 Po0.005
Metastasis
 37 20 (54.1%) 17 (45.9%)
Po0.005+ 37 3 (8.1%) 34 (91.9%)
3
75
i
Periostin overexpression and oral cancer
BSMS Siriwardena et al
1400
British Journal of Cancer (2006) 95(10), 1396 – 1403 & 2006 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
correlation between Periostin expression and clinicopathological
findings including invasion pattern and metastasis in OSCC cases.
In fact, 14 of 23 (61%) cases showed patterns I and II (a solid sheet
of tumour with a pushing border and large tumour islands) and
no cases showed pattern IV in Periostin-negative cases, suggesting
that Periostin-negative cells may not be able to detach from
tumour nests. We also found Periostin expression was well
correlated with blood vessels density. Interestingly, Periostin-
negative cases showed lower blood vessel density in comparison
with Periostin-positive cases. In addition, recombinant Periostin
enhanced capillary formation by in vitro angiogenesis assay. These
findings strongly suggest that Periostin may promote angiogenesis
as well as invasion of OSCC cells.
The four internal repeats region of Periostin share a homology
with the axon guidance protein FAS1, containing sequences that
allows binding of integrins and glycosaminoglycans in vivo (Elkins
et al, 1990). FAS1 domains of big-h3, which shares a significant
structural homology with Periostin, bear motifs interacting with
integrins a3b1 and avb5 (Kim et al, 2000, 2002) and mediate
endothelial cell adhesion and migration via integrin avb3 (Nam
et al, 2003). Similar to big-h3, we also previously found that
interference with the function of integrins by specific anti-avb3
and anti-avb5 integrin antibodies had an effect on the ability of
Periostin to mediate cell adhesion in OSCC cells (Kudo et al, 2006).
These findings strongly suggest that FAS1 domain of Periostin may
be important for binding to integrins both in cancer cells and
endothelial cells.
Taken together with previous and present studies, we hypothe-
sise that invasion and angiogenesis promoted by Periostin may
lead to metastasis of OSCC through the following steps: (i)
Periostin-overexpressing OSCC cells secrete Periostin, (ii) secreted
Periostin binds to integrins both in OSCC cells and endothelial
cells, (iii) interaction between Periostin and integrins promotes
invasion through inhibition of interaction between integrins and
ECM and/or activation of intracellular signal in OSCC cells, (iv)
interaction between Periostin and integrins promotes angiogenesis
in endothelial cells and (v) invasion and angiogenesis leads to
metastasis (Figure 4). Overall, our present findings suggest that
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Figure 3 Correlation between Periostin expression and blood vessel density. (A) Blood vessel density is plotted against Periostin expression. First, we
have stained all OSCC cases with CD34 endothelial marker. For evaluating blood vessel density, we performed histomorphometric analysis as described in
Materials and Methods. From three representative areas, total count of blood vessels per stromal area was quantitatively analysed and the average was
calculated. For the correlation between Periostin expression and blood vessel density, statistical significance was measured by the Welch test. Periostin
expressed tumours showed higher vascular density compared to negative tumours and the results were significant statistically. (B) Immunohistochemical
expression of CD34. Representative cases of CD34 expression are shown. Periostin-positive tumour shows higher number of vessels ( 100). (C) Periostin
enhanced capillary formation in vitro. Representative areas of capillary formation by Periostin treatment (0, 50, 100 and 250 ngml1) are shown ( 40). An
angiogenesis assay kit was used according to the manufacturer’s instructions with minor modification (Fox et al, 1995). Human umbilical vein endothelial cells
were treated with different concentrations of recombinant Periostin protein (0, 50, 100 and 250 ngml1) and changed media every 3 days. After 12 days,
the cells were fixed and stained with anti-human CD31 antibody as described in Materials and Methods. Tubule score was analysed under a bright-field
microscope. (D) The graph shows average tubule score after Periostin treatment. The values represent means of tubule score7s.d. based on 3wells data
point in a single experiment. Tubule score was evaluated by the Chalkley count method (Sawair et al, 2003).
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Periostin can be a useful marker to predict metastasis in OSCC. It
has been reported that serum levels of Periostin were elevated in
patients with breast cancer, nonsmall-cell lung cancer and
thymoma (Sasaki et al, 2001a, b and 2003). In fact, we detected
Periostin in condition media of oral cancer cell lines with high
expression of Periostin (Kudo et al, 2006). Therefore, we can
imagine that secreted Periostin from OSCC cells can probably be
detected in saliva and/or blood from the patients. We will do the
detection of Periostin in the serum of patients with OSCC in the
future. In conclusion, our studies have demonstrated a critical role
of Periostin in invasion and angiogenesis of the metastatic process.
These findings provide new and important information on the
progression of OSCC. Our present findings raise the possibility
that it could be used as a molecular target in antimetastatic therapy
of OSCC patients.
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